Meigs’ syndrome (MS), a rare complication of benign ovarian tumors, is easily misdiagnosed as ovarian cancer (OC). We retrospectively reviewed the clinical laboratory data of patients diagnosed with MS from 2009 to 2018. Serum carbohydrate antigen 125 and HE4 levels were higher in the MS group than in the ovarian thecoma-fibroma (OTF) and healthy control groups (all <0.05). However, the serum HE4 levels were lower in the MS group than in the OC group ( <0.001). A routine blood test showed that the absolute counts and percentages of lymphocytes were significantly lower in the MS group than in the OTF and control groups (all <0.05). However, these variables were higher in the MS group than in the OC group (both <0.05). The neutrophil-to-lymphocyte ratio (NLR) was also significantly lower, whereas the lymphocyte-to-monocyte ratio was higher in the MS group than in the OC group (both <0.05). The NLR, platelet-to-lymphocyte ratio, and systemic immune index were significantly higher in the MS group than in the OTF and control groups (all <0.05). The hypoxia-inducible factor-1 mRNA levels were also significantly higher, whereas the glucose transporter 1, lactate dehydrogenase, and enolase 1 mRNA levels were lower in peripheral CD4 T cells obtained preoperatively in a patient with MS than those in patients with OTF, patients with OC, and controls (all <0.05). The expression of these four glucose metabolism genes was preferentially restored to normal levels after the tumor resection of MS ( <0.001). These clinical laboratory features can be useful in improving the preoperative diagnostic accuracy of MS.